Viatris completes Pacira acquisition, projects $100M revenue boost

Advertisement

Viatris has completed its acquisition of Pacira BioSciences, a non-opioid pain management company.

The transaction closed Nov. 17, after Viatris accepted for payment approximately 32,929,780 shares, representing approximately 66.46% of Pacira’s outstanding stock, tendered at $36.50 per share in cash.

Viatris then merged Pacira’s remaining shares into the deal without a Pacira stockholder vote, converting them into the right to receive the same $36.50 per share. Pacira is now a wholly owned subsidiary of Viatris, and its shares will be delisted from the Nasdaq Global Select Market. The acquisition was first announced Oct. 8.

Viatris expects the acquisition to contribute $90 million to $100 million in revenue for the remainder of 2026, from Nov. 17 through Dec. 31.

The deal is part of Viatris’ strategy to strengthen its U.S. innovative medicines business, CEO Scott Smith said, with the combined company aiming to establish a leadership position in non-opioid pain management.

Advertisement

Next Up in Pharmacy

Advertisement